Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression

Jun Zhang; Yulin Wang; Yan Wang; Huafeng Xiao; Xinjing Chen; Yifei Lei; Zhebin Feng; Xiaodong Ma; Lin Ma

doi:10.21037/qims-22-32

Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression

Quant Imaging Med Surg. 2022 Oct;12(10):4805-4822. doi: 10.21037/qims-22-32.

Authors

Jun Zhang^#^{1

2}, Yulin Wang^#¹, Yan Wang¹, Huafeng Xiao¹, Xinjing Chen¹, Yifei Lei³, Zhebin Feng³, Xiaodong Ma³, Lin Ma¹

Affiliations

¹ Department of Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
² Department of Radiology, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China.
³ Department of Neurosurgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

^# Contributed equally.

Abstract

Background: Tumor recurrence and pseudoprogression (PsP) have similar imaging manifestations in conventional magnetic resonance imaging (MRI), although the subsequent treatments are completely different. This study aimed to evaluate the value of perfusion-weighted imaging (PWI) in differentiating PsP from glioma recurrence.

Methods: A comprehensive literature search was performed to evaluate clinical studies focused on differentiating recurrent glioma from PsP using PWI, including dynamic susceptibility contrast MRI (DSC-MRI), dynamic contrast enhanced MRI (DCE-MRI), and arterial spin labeling (ASL). Study selection and data extraction were independently completed by two reviewers. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was applied to evaluate the quality of the included studies. The software Stata 16.0 and Meta-Disc 1.4 were used for the meta-analysis. Meta-regression and subgroup analyses were applied to identify the sources of heterogeneity in the studies. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) prior to initiation (CRD42022304404).

Results: A total of 40 studies were included, including 27 English studies and 13 Chinese studies. There were 1,341 patients with glioma recurrence and 876 patients with PsP. The pooled sensitivity and specificity of DSC-MRI for differentiating glioma recurrence from PsP were 0.82 [95% confidence interval (CI): 0.78 to 0.86] and 0.87 (95% CI: 0.80 to 0.92), respectively. The pooled sensitivity and specificity of DCE-MRI were 0.83 (95% CI: 0.76 to 0.89) and 0.83 (95% CI: 0.78 to 0.87), respectively. The pooled sensitivity and specificity of ASL were 0.80 (95% CI: 0.73 to 0.86) and 0.86 (95% CI: 0.76 to 0.92), respectively.

Discussion: The DSC-MRI, DCE-MRI, and ASL perfusion techniques displayed high accuracy in distinguishing glioma recurrence from PsP, and DSC-MRI had a higher diagnostic performance than the other two techniques. However, due to the diversity of the parameters and threshold differences, further investigation and standardization are needed.

Keywords: Perfusion-weighted imaging (PWI); glioma; meta-analysis; pseudoprogression (PsP); tumor recurrence.